505 related articles for article (PubMed ID: 21949687)
1. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
[TBL] [Abstract][Full Text] [Related]
4. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
5. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
6. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
7. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
9. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
12. Prolyl Hydroxylase 3 Knockdown Accelerates
Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
[TBL] [Abstract][Full Text] [Related]
13. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
14. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
Yin R; Liu S
Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
[TBL] [Abstract][Full Text] [Related]
15. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.
An J; Liu H; Magyar CE; Guo Y; Veena MS; Srivatsan ES; Huang J; Rettig MB
Cancer Res; 2013 Feb; 73(4):1374-85. PubMed ID: 23393199
[TBL] [Abstract][Full Text] [Related]
16. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
17. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
18. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
[TBL] [Abstract][Full Text] [Related]
20. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
